WO2023031969 - A METHOD OF IMPROVING STABILITY OF IMMUNE CHECK POINT INHIBITORS
National phase entry:
Publication Number
WO/2023/031969
Publication Date
09.03.2023
International Application No.
PCT/IN2022/050787
International Filing Date
02.09.2022
Title **
[English]
A METHOD OF IMPROVING STABILITY OF IMMUNE CHECK POINT INHIBITORS
[French]
PROCÉDÉ D'AMÉLIORATION DE LA STABILITÉ D'INHIBITEURS DU POINT DE CONTRÔLE IMMUNITAIRE
Applicants **
DR. REDDY’S LABORATORIES LIMITED
Inventors
JAYARAMAN, Murali
K GOUD, Saisharan
ASHOK NANKAR, Sunil
NANATH, Maya
SIGIREDDI, Indra Kumar
AGGARWAL, Lovisha
KALIGATLA, Sireesha Goswamy
MARIKANTY, Ravi Kumar
S, Abirami
SIVALANKA, Giridhar
PENMETSA, Ravi Kiranmai
LABALA, Suman
INGALE, Mahesh
SARKAR, Puja
DESAI, Mayur Vijay
KIRAVE, Prathibha Chandrashekhar
SHINDE, Chetan Govindrao
Priority Data
202141040075
03.09.2021
IN
202241019550
31.03.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2101 | |
| EPO | Filing, Examination, Granting | 11930 | |
| Japan | Filing, Examination, Granting | 2016 | |
| South Korea | Filing, Examination, Granting | 1826 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,613
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human programmed death receptor-1 (PD-1)/ programmed death receptor Ligand 1 (PD-Ll), and method for preparing the same. The disclosed formulations stabilizes anti-PD1/anti-PD L1 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).[French]
La présente invention concerne des formulations pharmaceutiques d'anticorps et de fragments de liaison à l'antigène contre le récepteur 1 de mort programmée humain (PD-1)/ligand du récepteur de mort programmée 1 (PD-L1), et leur procédé de préparation. Les formulations décrites stabilisent l'anticorps anti-PD1/anti-PD-L1 depuis de faibles concentrations jusqu'à des concentrations plus élevées, ce qui les rend appropriées pour différents modes d'administration (sous-cutanée/intraveineuse).